The Global Companion Diagnostics Market was valued at USD 6.89 billion in 2023 and is projected to reach USD 18.23 billion by 2031, growing at a CAGR of 12.94% from 2024 to 2031. The market is witnessing significant expansion as pharmaceutical companies, healthcare providers, and diagnostic laboratories increasingly adopt companion diagnostic technologies to support personalized medicine and targeted therapies. Companion diagnostics help identify patients who are most likely to benefit from a particular treatment, enabling healthcare professionals to make more informed therapeutic decisions. The rising prevalence of cancer and other chronic diseases, increasing investments in precision medicine, advancements in molecular diagnostics, and the growing development of targeted therapeutics are among the major factors expected to drive market growth throughout the forecast period.
Get the Full Detailed Insights Report: https://www.kingsresearch.com/companion-diagnostics-market-659
Key Highlights of the Companion Diagnostics Market
- Market Size in 2023: USD 6.89 Billion
- Projected Market Size by 2031: USD 18.23 Billion
- CAGR (2024–2031): 12.94%
- Increasing adoption of personalized and precision medicine
- Growing demand for targeted cancer therapies
- Rising investments in molecular diagnostics and genomic technologies
- Increasing integration of companion diagnostics into pharmaceutical drug development
- Rapid technological advancements in next-generation sequencing and polymerase chain reaction
- Expanding use of biomarker testing in clinical trials and treatment selection
- Growing collaborations between pharmaceutical companies and diagnostic developers
Companion Diagnostics Market Overview
The companion diagnostics market is emerging as a critical component of modern healthcare, supporting the transition from traditional treatment approaches toward personalized and precision medicine. Companion diagnostics are tests or diagnostic tools developed to provide information that is essential for the safe and effective use of a specific therapeutic product. These tests can identify biomarkers that indicate whether a patient is likely to respond positively to a particular drug or whether they may experience adverse reactions.
The growing importance of personalized medicine is significantly increasing demand for companion diagnostics. Rather than relying on a one-size-fits-all approach, physicians and healthcare providers can use molecular and genetic information to select treatments based on an individual patient’s biological characteristics. This approach can improve therapeutic outcomes while potentially reducing unnecessary treatment and healthcare expenditure.
The cancer treatment landscape is one of the largest contributors to market expansion. Oncology has experienced rapid development in targeted therapies and immunotherapies, creating an increasing requirement for diagnostic testing that identifies relevant biomarkers. Companion diagnostics can help determine the presence or absence of molecular characteristics associated with treatment response.
In addition to oncology, companion diagnostics are expanding into neurological diseases, infectious diseases, and cardiovascular conditions. Advances in genomics, molecular biology, immunology, and bioinformatics are allowing diagnostic developers to identify increasingly complex biomarkers and develop sophisticated testing platforms.
The pharmaceutical and biopharmaceutical industries are also integrating companion diagnostics earlier into drug development programs. The use of these tests during clinical trials can assist companies in identifying suitable patient populations, improving trial design, and generating evidence supporting targeted therapeutic approaches.
Growth Drivers of the Companion Diagnostics Market
Increasing Adoption of Personalized Medicine
The increasing adoption of personalized medicine is one of the most significant factors supporting the growth of the companion diagnostics market. Personalized medicine uses patient-specific information, including genetic, molecular, and clinical characteristics, to guide treatment decisions.
Traditional therapies may provide varying results among patients because individuals can respond differently to the same drug. Companion diagnostics help address this challenge by identifying biomarkers associated with therapeutic response.
As healthcare systems increasingly focus on improving treatment outcomes and reducing ineffective therapies, demand for diagnostic solutions capable of supporting personalized treatment decisions is expected to rise.
Rising Prevalence of Cancer
The growing global burden of cancer is a major factor contributing to demand for companion diagnostics. Cancer is a highly heterogeneous disease, with patients having different molecular characteristics even when diagnosed with the same cancer type.
The development of targeted cancer therapies has increased the importance of biomarker testing. Companion diagnostics can help identify genetic mutations, protein expression patterns, and other biomarkers that determine whether a patient may benefit from a specific treatment.
The increasing use of targeted therapies and immunotherapies is therefore expected to create substantial opportunities for companion diagnostic developers.
Increasing Development of Targeted Therapies
Pharmaceutical and biopharmaceutical companies are increasingly focusing on therapies designed to target specific molecular pathways or biomarkers. This trend is encouraging the development of associated diagnostic tests.
Companion diagnostics can be integrated into the drug development process to identify appropriate patient populations and assess treatment response. As targeted drug pipelines expand, the need for corresponding diagnostic technologies is expected to increase.
Growing Pharmaceutical and Diagnostic Partnerships
Collaborations between pharmaceutical companies and diagnostic technology providers are becoming increasingly important. Pharmaceutical companies often work with specialized diagnostic developers to develop, validate, and commercialize companion diagnostic tests alongside therapeutics.
These collaborations can accelerate the development of precision medicine solutions while allowing pharmaceutical companies to strengthen their clinical development strategies.
Increasing Investments in Genomic Technologies
Advancements in genomic technologies are improving the ability to detect mutations and other biomarkers associated with disease and treatment response. Next-generation sequencing and other molecular diagnostic technologies can analyze large quantities of genetic information, creating new possibilities for companion diagnostic applications.
Increasing investments in genomics research and molecular diagnostics are therefore expected to support the market’s long-term expansion.
Latest Trends in the Companion Diagnostics Market
Rapid Adoption of Next-Generation Sequencing
Next-generation sequencing is becoming increasingly important in companion diagnostics due to its ability to analyze multiple genetic targets simultaneously. NGS can support comprehensive biomarker profiling and is particularly valuable in complex diseases such as cancer.
The technology is increasingly being integrated into clinical research and oncology testing, where identifying multiple genetic alterations can help physicians and researchers understand disease biology and therapeutic response.
Growing Use of Liquid Biopsy
Liquid biopsy is emerging as an important technology in precision medicine. Unlike traditional tissue biopsy, liquid biopsy can analyze biomarkers present in blood and other biological fluids.
The growing interest in minimally invasive diagnostic methods is supporting research into circulating tumor DNA and other biomarkers. Liquid biopsy may provide opportunities for monitoring disease progression, treatment response, and the emergence of resistance.
Integration of Artificial Intelligence and Data Analytics
Artificial intelligence and advanced data analytics are increasingly being incorporated into genomic and diagnostic workflows. AI-based technologies can help researchers analyze complex molecular datasets and identify relationships between biomarkers and treatment outcomes.
The combination of AI, genomic data, and companion diagnostics could improve biomarker discovery and support more precise patient stratification.
Expansion Beyond Oncology
Although oncology remains a major application area, companion diagnostics are increasingly being investigated for neurological, infectious, and cardiovascular diseases.
The expansion into these indications is creating opportunities for diagnostic developers to diversify their product portfolios and address broader healthcare needs.
Increasing Use in Clinical Trials
Pharmaceutical companies are increasingly using companion diagnostic technologies during clinical trials to identify appropriate patient populations. Biomarker-based patient selection can improve the efficiency of clinical research and help demonstrate the effectiveness of targeted therapies.
Companion Diagnostics Market Segmentation Analysis
By Technology
Polymerase Chain Reaction
Polymerase chain reaction (PCR) represents an important technology in the companion diagnostics market due to its established role in detecting specific genetic sequences and molecular biomarkers.
PCR-based companion diagnostics offer high sensitivity and specificity and can be used to identify genetic alterations relevant to treatment decisions. The technology is widely utilized in oncology and infectious disease testing.
The established laboratory infrastructure supporting PCR technology and its relatively efficient testing workflow are expected to maintain demand throughout the forecast period.
Next-Generation Gene Sequence
Next-generation sequencing is expected to experience strong growth due to its ability to identify multiple genetic alterations within a single test. NGS platforms can provide comprehensive genomic profiles that are particularly valuable in precision oncology.
As the number of targeted therapies increases, healthcare providers and pharmaceutical companies require advanced technologies capable of identifying multiple biomarkers. NGS is well positioned to meet this requirement.
Increasing investments in genomic medicine and declining sequencing costs are further supporting the adoption of NGS-based companion diagnostics.
Immunohistochemistry
Immunohistochemistry remains an important diagnostic technology, particularly within oncology. It enables healthcare professionals to detect and analyze specific proteins within tissue samples.
IHC-based testing is used to assess biomarker expression and can support treatment selection for patients with specific cancers. The established use of immunohistochemistry in pathology laboratories and hospitals is expected to contribute to sustained market demand.
By End User
Pharmaceutical & Biopharma Companies
Pharmaceutical and biopharmaceutical companies represent a major end-user group in the companion diagnostics market. These companies increasingly incorporate diagnostic testing into drug discovery, clinical trials, regulatory strategies, and commercialization programs.
The integration of companion diagnostics can help drug developers identify patient populations most likely to benefit from a targeted therapy.
As pharmaceutical pipelines become increasingly focused on precision therapeutics, demand from this segment is expected to grow significantly.
Reference Laboratories
Reference laboratories play an important role in companion diagnostics by providing specialized testing services to hospitals, physicians, pharmaceutical companies, and research organizations.
These laboratories often possess advanced molecular testing infrastructure and specialized expertise required for complex biomarker analysis.
The growing outsourcing of diagnostic testing and increasing demand for specialized molecular analysis are expected to support this segment.
Contract Research Organizations
Contract research organizations (CROs) are increasingly involved in clinical research and drug development programs that require biomarker identification and patient stratification.
CROs can support pharmaceutical companies by conducting diagnostic testing during clinical trials and generating data required for evaluating targeted therapies.
The growing outsourcing of clinical research activities is therefore expected to create additional opportunities for the companion diagnostics market.
By Indication
Cancer
Cancer represents one of the most important indications for companion diagnostics. The high molecular diversity of cancer has increased the need for biomarker testing to determine the most suitable treatment strategy.
Companion diagnostics can help identify mutations, protein expression, and other molecular characteristics associated with treatment response.
The increasing development of targeted cancer therapies, immunotherapies, and biomarker-driven treatments is expected to maintain cancer’s leading position in the market.
Neurological Diseases
Neurological diseases represent an emerging opportunity for companion diagnostics. Advances in neuroscience and molecular biology are improving understanding of the biological mechanisms associated with neurological disorders.
The development of precision therapeutics for neurological conditions could increase the demand for diagnostic tests capable of identifying patients who are most likely to respond to specific treatments.
Infectious Diseases
Companion diagnostics are increasingly being explored for infectious diseases, particularly where pathogen characteristics or patient-specific factors influence treatment selection.
Molecular diagnostic technologies can enable rapid identification of infectious agents and relevant genetic characteristics, supporting more targeted therapeutic approaches.
The increasing focus on antimicrobial resistance is also creating opportunities for advanced diagnostic technologies that can help guide treatment decisions.
Cardiovascular Diseases
The cardiovascular disease segment is expected to experience growing interest as researchers identify biomarkers associated with disease progression and therapeutic response.
The application of molecular diagnostics in cardiovascular medicine could support patient stratification and enable more personalized approaches to treatment.
Regional Analysis
North America
North America is expected to maintain a significant position in the global companion diagnostics market due to the presence of advanced healthcare infrastructure, strong pharmaceutical and biotechnology industries, and extensive research capabilities.
The region benefits from substantial investments in precision medicine, molecular diagnostics, genomic research, and targeted therapies.
The United States represents a major contributor to regional growth, supported by pharmaceutical innovation and increasing adoption of advanced diagnostic technologies.
Europe
Europe represents another important market for companion diagnostics. The region has a strong healthcare infrastructure, established pharmaceutical industry, and increasing emphasis on precision medicine.
Growing research activities in molecular diagnostics and genomics are supporting the adoption of companion diagnostic solutions. European healthcare organizations are also increasingly focused on improving treatment outcomes and optimizing healthcare resources.
The increasing development of targeted therapies and investments in cancer research are expected to contribute to regional market expansion.
Asia-Pacific
Asia-Pacific is expected to witness strong growth during the forecast period. Increasing healthcare investments, rising awareness regarding precision medicine, expanding pharmaceutical industries, and improving diagnostic infrastructure are supporting market development.
Countries such as China, Japan, South Korea, and India are investing in genomic research and advanced molecular diagnostic technologies.
The region’s large patient population and increasing prevalence of cancer and other chronic diseases are expected to create substantial opportunities for companion diagnostic manufacturers.
Latin America
Latin America is expected to experience steady growth as healthcare infrastructure improves and the adoption of advanced diagnostic technologies increases.
The expansion of pharmaceutical and biotechnology activities and increasing awareness of personalized treatment approaches are expected to create new opportunities.
Middle East & Africa
The Middle East & Africa region is expected to witness gradual adoption of companion diagnostic technologies. Improvements in healthcare infrastructure, increasing investments in specialized medical facilities, and growing awareness of advanced diagnostic methods are supporting market development.
As healthcare systems across the region increasingly focus on early disease detection and precision treatment, demand for molecular diagnostic solutions is expected to increase.
Competitive Landscape
The global companion diagnostics market is characterized by increasing competition among diagnostic technology developers, molecular testing companies, pharmaceutical organizations, and specialized precision medicine providers.
Leading market participants are focusing on product development, strategic partnerships, regulatory approvals, technological innovation, acquisitions, and collaborations with pharmaceutical companies to strengthen their market presence.
Companies operating across the broader companion diagnostics ecosystem include F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, QIAGEN N.V., Agilent Technologies, Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, Foundation Medicine, Inc., and Laboratory Corporation of America Holdings, among other industry participants.
F. Hoffmann-La Roche Ltd.
Roche has established a strong position in precision medicine through its combination of pharmaceutical and diagnostic capabilities. Its integrated approach allows diagnostic testing to support targeted therapeutic development and patient management.
Thermo Fisher Scientific Inc.
Thermo Fisher Scientific provides molecular diagnostic, genomic, and laboratory technologies that support biomarker research and precision medicine applications.
The company’s broad portfolio of sequencing and molecular biology technologies supports applications across pharmaceutical research and clinical diagnostics.
Abbott Laboratories
Abbott operates across diagnostics and healthcare technologies and provides testing solutions that support disease diagnosis and patient management.
Its diagnostic capabilities contribute to the broader development of personalized healthcare approaches.
QIAGEN N.V.
QIAGEN develops molecular testing and sample preparation technologies used in research and clinical applications. Its molecular diagnostic solutions support biomarker identification and precision medicine workflows.
Agilent Technologies, Inc.
Agilent provides laboratory and diagnostic technologies used across genomics, pathology, and life sciences research. Its technologies support molecular analysis and biomarker-related applications.
Illumina, Inc.
Illumina is a major genomics technology company whose sequencing platforms support genomic analysis and biomarker research. Next-generation sequencing is increasingly important in precision oncology and companion diagnostics.
Bio-Rad Laboratories, Inc.
Bio-Rad provides life science research and diagnostic technologies, including molecular testing platforms used across clinical and research applications.
Danaher Corporation
Danaher operates through a broad portfolio of life sciences and diagnostics businesses. Its technologies contribute to molecular diagnostics, pathology, and precision medicine applications.
Foundation Medicine, Inc.
Foundation Medicine focuses on genomic profiling and precision oncology. Its comprehensive genomic testing capabilities support the identification of molecular alterations relevant to targeted cancer treatments.
Laboratory Corporation of America Holdings
Laboratory Corporation of America Holdings provides laboratory testing and clinical research services. Its extensive testing infrastructure supports biomarker analysis and pharmaceutical research programs.
Future Outlook
The companion diagnostics market is expected to experience significant growth through 2031 as healthcare systems increasingly shift toward personalized and precision medicine. The projected increase from USD 6.89 billion in 2023 to USD 18.23 billion by 2031 reflects the growing importance of biomarker-based treatment strategies.
The future development of the market will be strongly influenced by advancements in genomic sequencing, molecular diagnostics, artificial intelligence, liquid biopsy, and biomarker discovery. As pharmaceutical companies increasingly develop targeted therapies, companion diagnostics will become an increasingly important component of drug development and commercialization.
Oncology is expected to remain a leading application area, supported by the continued development of targeted cancer therapies and immunotherapies. However, opportunities are likely to expand across neurological diseases, infectious diseases, cardiovascular diseases, and other therapeutic areas.
Next-generation sequencing is expected to play a particularly important role in the future of companion diagnostics. Its ability to analyze multiple genetic markers simultaneously can provide comprehensive information that supports increasingly complex treatment decisions.
The integration of artificial intelligence and bioinformatics may further enhance the ability of healthcare professionals and researchers to interpret complex molecular datasets. These technologies could support faster biomarker discovery and improve patient stratification.
Pharmaceutical and diagnostic company collaborations will also remain an important feature of the competitive environment. As drug developers seek to improve clinical trial outcomes and demonstrate the value of targeted treatments, partnerships with diagnostic companies can provide access to specialized testing capabilities.
Overall, the companion diagnostics market is positioned for strong expansion during the forecast period. Increasing healthcare personalization, technological advancements, rising chronic disease prevalence, and the growing pipeline of targeted therapies are expected to create significant opportunities for market participants worldwide.
Conclusion
The Companion Diagnostics Market is undergoing a significant transformation as precision medicine becomes increasingly important in modern healthcare. The market’s projected growth to USD 18.23 billion by 2031 at a CAGR of 12.94% highlights the rising demand for technologies that can connect diagnostic information with targeted treatment decisions.
Technologies such as polymerase chain reaction, next-generation sequencing, and immunohistochemistry will continue to play important roles in identifying biomarkers and supporting personalized therapies. Pharmaceutical and biopharmaceutical companies, reference laboratories, and contract research organizations will remain major end users as diagnostic testing becomes increasingly integrated into drug development and clinical care.
Cancer is expected to remain the leading indication, while emerging opportunities across neurological, infectious, and cardiovascular diseases could further expand the addressable market. At the regional level, North America and Europe are expected to maintain strong positions, while Asia-Pacific offers substantial growth opportunities due to improving healthcare infrastructure and increasing investments in genomic medicine.
With ongoing innovation in molecular diagnostics, genomics, AI, and biomarker research, companion diagnostics are expected to remain a fundamental component of the global shift toward more precise, personalized, and effective healthcare.
About Kings Research
Kings Research is a leading market research and consulting firm that provides comprehensive market intelligence and strategic insights to businesses across various industries. The company delivers syndicated reports, customized research, and consulting services designed to help organizations understand evolving market dynamics, identify growth opportunities, assess competitive landscapes, and make informed strategic decisions.
Through in-depth research methodologies, industry expertise, and data-driven analysis, Kings Research supports businesses in navigating emerging trends and developing effective growth strategies across global markets.
Explore More Articles:
UJ-Crystal Raises ¥430 Million to Advance Semiconductors
Industrial Foundation Models: The Next Leap for Manufacturing Intelligence